| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2001 | WO2001012162A1 Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof |
| 02/22/2001 | WO2001012161A1 Rapidly dissolving dosage form and process for making same |
| 02/22/2001 | WO2001012160A1 Microparticles for pulmonary administration |
| 02/22/2001 | WO2001012159A2 Artificial tear replacement solution |
| 02/22/2001 | WO2001012156A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001012144A1 Gums containing antimicrobial agents |
| 02/22/2001 | WO2001012130A1 Compositions and methods of treatment for skin conditions using extracts of turmeric |
| 02/22/2001 | WO2001012128A2 Antibacterial agents for the treatment of acute mucosal infections |
| 02/22/2001 | WO2001012103A1 Metering and packaging of controlled release medication |
| 02/22/2001 | WO2001011971A1 Natural, anti-bacterial, anti-inflammation, anti-virus, anti-herpes cream |
| 02/22/2001 | WO2001011967A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | WO2001011964A1 Ectoparasiticidal aqueous suspension formulations of spinosyns |
| 02/22/2001 | WO2001011963A1 Oral treatment of companion animals with ectoparasiticidal spinosyns |
| 02/22/2001 | WO2001011933A2 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000074677A3 Improved pharmaceutical formulations |
| 02/22/2001 | WO2000073330A3 Method and compositions relating to insulin resistance disorders |
| 02/22/2001 | WO2000072008A3 Identification of novel mechanisms of drug resistance |
| 02/22/2001 | WO2000071737A3 Improved retroviral production by inhibition of the enveloppe cell receptor |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000071105A3 Tricloroacetic acid for the preparation of solutions and/or compositions for the treatment of erosive and/or ulcerative lesions |
| 02/22/2001 | WO2000069470A3 Improved cellular uptake of bioactive agents |
| 02/22/2001 | WO2000063206A3 Thiazolidinedione derivative and its use as antidiabetic |
| 02/22/2001 | WO2000062808A3 Cobalamin conjugates useful as antitumor agents |
| 02/22/2001 | WO2000061122A3 Use of 6-methylmercaptopurine riboside in ophthalmologic compositions |
| 02/22/2001 | WO2000058314A3 Sulfamate containing macrocyclic immunomodulators |
| 02/22/2001 | WO2000057853A3 Pharmaceutical composition containing an extrusion additive |
| 02/22/2001 | WO2000055633A3 Methods of screening for colorectal cancer modulators |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000040614A3 Characterization of the soc/crac calcium channel protein family |
| 02/22/2001 | WO2000039716A3 Arylpropenylimidazoles as farnesyl-protein transferase inhibitors |
| 02/22/2001 | WO2000036107A3 Compositions and methods for therapy and diagnosis of ovarian cancer |
| 02/22/2001 | WO2000032588A3 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds |
| 02/22/2001 | WO2000023100A8 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 02/22/2001 | WO2000023065A8 Storable active substance concentrate with formoterol |
| 02/22/2001 | WO2000022094A3 Methods for inhibiting oxidative modification of proteins |
| 02/22/2001 | WO2000021549A8 A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5 |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | WO1999063992A8 Novel calcium channel drugs and uses |
| 02/22/2001 | WO1999050275A3 Macrolide lhrh antagonists |
| 02/22/2001 | WO1999047553A3 Bacterial yeal family members as targets for antimicrobial drug design |
| 02/22/2001 | WO1999046279A3 INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 02/22/2001 | DE19940220A1 Preparation for treating rheumatic joint diseases, e.g. arthritis, comprising injectable, induction heatable, iron oxide-based magnetic particles including radionuclide and cytotoxic agent |
| 02/22/2001 | DE19939756A1 New 1-(1-ethyl-piperidin-4-yl)-1-(phenyl or heterocyclyl)-alkanol derivatives, are 5-HT(2A) receptor antagonists useful e.g. for treating schizophrenia, depression, memory disorders or eating disorders |
| 02/22/2001 | DE19939578A1 New nucleic acid encoding hemocyanin, useful for gene therapy of tumors and for recombinant production of fusion proteins for vaccination |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | DE19939095A1 Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer Of coxsackie-derived vector system for gene transfer |
| 02/22/2001 | DE19938823A1 Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
| 02/22/2001 | DE19938668A1 Tränenersatzmittel Artificial tears |
| 02/22/2001 | DE19937361A1 Orale Darreichungsform The oral dosage form |
| 02/22/2001 | DE19936744A1 Phagozytenmodulatoren (insbesondere Phagozytenaktivatoren) zur Behandlung und/oder Prophylaxe thrombotischer, atherothrombotischer und/oder hämostaseologischer Erkrankungen Phagozytenmodulatoren (especially Phagozytenaktivatoren) for the treatment and / or prophylaxis of thrombotic, atherothrombotic and / or blood coagulation disorders |
| 02/22/2001 | CA2784789A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2689735A1 Compositions comprising modafinil for treatment of fatigue associated with multiple sclerosis |
| 02/22/2001 | CA2464845A1 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2414171A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 02/22/2001 | CA2393965A1 Ascididemin derivatives and their therapeutic applications |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2385487A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382090A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | CA2381993A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 02/22/2001 | CA2381976A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | CA2381975A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381968A1 Pharmaceutical compositions comprising 4-quinolones for treating cancers |
| 02/22/2001 | CA2381703A1 Oxyme amides and hydrazone amides having fungicidal activity |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2381352A1 Phenanthroline-7-one derivatives and their therapeutic uses |
| 02/22/2001 | CA2381090A1 Benzoic acid derivatives for the treatment of diabetes mellitus |
| 02/22/2001 | CA2380941A1 Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| 02/22/2001 | CA2380940A1 Substances and agents for positively influencing collagen |
| 02/22/2001 | CA2380932A1 Tissue augmentation material and methods |
| 02/22/2001 | CA2380928A1 Method of preventing adhesion with absorbable polyoxaesters |
| 02/22/2001 | CA2380908A1 Plasma substitute composition |
| 02/22/2001 | CA2380892A1 Formation of nanometer-scale structures |
| 02/22/2001 | CA2380883A1 Microparticles for pulmonary administration |
| 02/22/2001 | CA2380820A1 Neurotherapeutic clavulanate composition and method |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380814A1 Pyridomorphinans, thienomorphinans and use thereof |
| 02/22/2001 | CA2380798A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 02/22/2001 | CA2380786A1 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | CA2380775A1 Benzoic acid derivatives and their use as ppar receptor agonists |
| 02/22/2001 | CA2380753A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | CA2380741A1 An ophthalmic fluid for contact lenses comprising a glyceride |
| 02/22/2001 | CA2380653A1 Mycophenolate mofetil in association with peg-ifn-.alpha. |
| 02/22/2001 | CA2380643A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380596A1 Metering and packaging of controlled release medication |
| 02/22/2001 | CA2380449A1 Rapidly dissolving dosage form and process for making same |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2380373A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | CA2379544A1 New stilbenes with vascular damaging activity |